Daito Pharmaceutical Co logo

4577 - Daito Pharmaceutical Co Share Price

¥3640 0.0  0.0%

Last Trade - 29/09/20

Sector
Healthcare
Size
Mid Cap
Market Cap £368.9m
Enterprise Value £371.7m
Revenue £332.5m
Position in Universe 1135th / 3865
Bullish
Bearish
Unlock 4577 Revenue
Momentum
Relative Strength (%)
1m +6.65%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -20.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st May 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
34,059 36,371 37,984 39,876 41,135 44,991 48,500 50,500 +5.7%
+12.1 +15.7 -4.6 +14.2 +16.6 +9.4 -8.93 +13.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 May 2020, Daito Pharmaceutical Co.,Ltd. revenues increased 9% to Y44.99B. Net income applicable to common stockholders increased 12% to Y3.94B. Revenues reflect Drug Substance segment increase of 10% to Y24.21B, Formulation segment increase of 9% to Y20.53B. Net income benefited from Research and Development Expense(in SGA) decrease of 13% to Y1.4B (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 4577
Graphical History

Revenue

4577 Revenue Unlock 4577 Revenue

Net Income

4577 Net Income Unlock 4577 Revenue

Normalised EPS

4577 Normalised EPS Unlock 4577 Revenue

PE Ratio Range

4577 PE Ratio Range Unlock 4577 Revenue

Dividend Yield Range

4577 Dividend Yield Range Unlock 4577 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
4577 EPS Forecasts Unlock 4577 Revenue
Profile Summary

Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Directors
Last Annual May 31st, 2020
Last Interim May 31st, 2020
Incorporated June 30, 1942
Public Since March 24, 2010
No. of Shareholders: 2,298
No. of Employees: 784
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Tokyo Stock Exchange
Shares in Issue 13,713,620
Free Float (0.0%)
Eligible for
ISAs
SIPPs
4577 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 4577
Upcoming Events for 4577
Tuesday 13th October, 2020
Q1 2021 Daito Pharmaceutical Co Ltd Earnings Release
Friday 27th November, 2020
Dividend For 4577.T - 23.0000 JPY
Frequently Asked Questions for Daito Pharmaceutical Co
What is the Daito Pharmaceutical Co share price?

As of 29/09/20, shares in Daito Pharmaceutical Co are trading at ¥3640, giving the company a market capitalisation of £368.9m. This share price information is delayed by 15 minutes.

How has the Daito Pharmaceutical Co share price performed this year?

Shares in Daito Pharmaceutical Co are currently trading at ¥3640 and the price has moved by 20.53% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Daito Pharmaceutical Co price has moved by 11.4% over the past year.

What are the analyst and broker recommendations for Daito Pharmaceutical Co?

Of the analysts with advisory recommendations for Daito Pharmaceutical Co, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Daito Pharmaceutical Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Daito Pharmaceutical Co next release its financial results?

Daito Pharmaceutical Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-05-31
What is the Daito Pharmaceutical Co dividend yield?

The Daito Pharmaceutical Co dividend yield is 1.1% based on the trailing twelve month period.

Does Daito Pharmaceutical Co pay a dividend?

Last year, Daito Pharmaceutical Co paid a total dividend of 40, and it currently has a trailing dividend yield of 1.1%. Looking ahead, shares in Daito Pharmaceutical Co are due to go ex-dividend on 2020-11-27 and the next dividend pay date is 2021-02-01.

When does Daito Pharmaceutical Co next pay dividends?

Daito Pharmaceutical Co are due to go ex-dividend on 2020-11-27 and the next dividend pay date is 2021-02-01. The historic dividend yield on Daito Pharmaceutical Co shares is currently 1.1%.

How do I buy Daito Pharmaceutical Co shares?

To buy shares in Daito Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Daito Pharmaceutical Co?

Shares in Daito Pharmaceutical Co are currently trading at ¥3640, giving the company a market capitalisation of £368.9m.

Where are Daito Pharmaceutical Co shares listed? Where are Daito Pharmaceutical Co shares listed?

Here are the trading details for Daito Pharmaceutical Co:

Country of listing: Japan
Exchange: TYO
Ticker Symbol: 4577
What kind of share is Daito Pharmaceutical Co?

Based on an overall assessment of its quality, value and momentum, Daito Pharmaceutical Co is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Daito Pharmaceutical Co share price forecast 2020?

We were not able to load any forecast data for Daito Pharmaceutical Co.

How can I tell whether the Daito Pharmaceutical Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daito Pharmaceutical Co. Over the past six months, the relative strength of its shares against the market has been 2.43%. At the current price of ¥3640, shares in Daito Pharmaceutical Co are trading at 5.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Daito Pharmaceutical Co PE Ratio?

The Daito Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 11.8. The shares are currently trading at ¥3640.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Daito Pharmaceutical Co?

Daito Pharmaceutical Co's management team is headed by:

Yasunobu Ohtsuga - PRE
Masamichi Takimoto - MEO
Hiroshi Kawahara - EXO
Kenji Fujita - EXO
Mitsuo Hirono - MEO
Junichi Kikuta - SMD
Hisao Abe - DHR
Masuo Nomura - MEO
Kazushige Hizume - EXO
Atsushi Saino - IND
Masahiro Harai - EXO
Who are the major shareholders of Daito Pharmaceutical Co?

Here are the top five shareholders of Daito Pharmaceutical Co based on the size of their shareholding:

Sumitomo Mitsui Trust Asset Management Co., Ltd. Investment Advisor
Percentage owned: 4.13% (566k shares)
Northern Trust Co. (AVFC) Re HCR00 Corporation
Percentage owned: 4.09% (561k shares)
Sasayama (Shinjiro) Individual Investor
Percentage owned: 2.55% (350k shares)
Nomura Asset Management Co., Ltd. Investment Advisor
Percentage owned: 2.5% (343k shares)
Nomura TOPIX ETF Mutual Fund
Percentage owned: 2.45% (336k shares)
Similar to 4577
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.